President Donald Trump speaks speaks on the latest developments of the coronavirus outbreak, while flanked by White House coronavirus response coordinator Debbie Birx (L), and U.S. Surgeon General Jerome Adams (R), in the James Brady Press Briefing Room at the White House March 19, 2020. (Photo by Chip Somodevilla/Getty Images)
President Donald Trump in a press conference on Thursday said the Food and Drug Administration is fast-tracking efforts to approve an antiviral therapy, best known for treating malaria, for use in coronavirus cases.
The drug, hydroxychloroquine, was developed more than a half-century ago and is approved for treating malaria, arthritis, and other ailments. Reports out of China and Italy suggest the drug may help, but there is no hard data yet.
"We're going to be able to make that drug available almost immediately," Trump said.
The FDA is working to conduct a "large, pragmatic clinical trial" quickly to confirm the drug's benefit to coronavirus patients, said Commissioner Dr. Stephen Hahn.
He also tempered the president's optimism about the still-untested solution.
"What's also important is not to provide false hope," he said. "We may have the right drug, but it might not be in the appropriate dosage form right now, and it might do more harm than good."
New antiviral therapies face a shorter and less arduous approval process than vaccines, several of which are under development with 12 to 18-month timelines.
"The therapies are something we could move on much faster potentially," Trump said.
He claimed the administration "slashed red tape" to develop new vaccines and therapies.
The president also held out on confirming whether he would invoke the Defense Production Act, which he signed on Wednesday, to mandate the production of needed medical supplies such as N95 respirators and surgical masks.
"If we find that we need something, then we will do that," he said.
Trump repeated that he was open to the federal government buying equity stakes in the airline, cruise, hospitality, and other industries hurt by the outbreak.
The press conference opened with more controversial language placing the blame squarely on China for the outbreak, despite concerns voiced about potentially exacerbating a backlash against Asian Americans.
"We continue our relentless effort to defeat the Chinese virus," Trump said.
Emily Hoeven, newsletter editor at CalMatters, joins Cheddar News to discuss California Governor Gavin Newsom's gun law modeled after Texas's abortion law.
Chuck Rocha, host of 'Nuestro' podcast and opinion contributor at The New York Times, joins Cheddar News to discuss why Democrats are losing Hispanic voters.
More businesses are requiring workers to return to the office, but there is concern that many employees in the middle class, especially women and people of color, need remote work options for reasons including childcare and financial security. Joan Williams, director of the Center for WorkLife Law at the University of California, joined Cheddar to discuss why office mandates could be detrimental to the middle class. She noted that while companies claim a return to offices would help foster more collaboration and efficiency, reports show that they are successfully able to do their jobs from home.
The U.S. postal service has confirmed that it secretly developed and tested a blockchain-based mobile voting system ahead of the 2020 election. Susan Greenhalgh, senior advisor on election security, Free Speech for People, joins Cheddar News to discuss the cybersecurity complications of a mobile voting system.
The U.S. Supreme Court ruled to allow the controversial Texas abortion law to remain in effect, banning abortion at six weeks and allowing any private citizen to sue a person or doctor aiding or abetting someone seeking an abortion. Outraged at this decision, California Governor Gavin Newsom is working to draft a proposal in line with the law as it relates to guns. Shawn Hubler, California correspondent at the New York Times, joins Cheddar News to discuss.
Even as tech giant Google implements a vaccination mandate, charging its employees to declare their vaccine status within a time frame or risk dismissal, the federal government is tangled up in the court system trying to impose one of its own. Cindy Cohn, the executive director of the Electronic Frontier Foundation, and Harry Nelson, founder and managing partner of Nelson Hardiman LLP, joined Cheddar to debate the ethics, efficacy, and legality surrounding the issue. While Cohn noted that she thinks the federal mandate might be legally sound, her organization is also concerned with a separate question of privacy. "At EFF what we're most interested in is the digital surveillance that's going along with some of these attempts to try to track and confirm whether people are vaccinated or not," she said.
